Trade Brains

FEBRUARY 21, 2024

crores plus taxes Scope: Implementation and management of IT infrastructure Client: Central Board of Indirect Taxes and Customs (CBIC), Ministry of Finance, Govt of India Missile Systems Spares Order from Mazagon Dock Shipbuilders Ltd Value: Rs. The company’s export sales increased by approximately 45% to USD 48.33

Electronics

Trade Brains

MAY 15, 2024

until 2030. While looking at the net profit MRPL profit decreased by 10.23% because of increased payment of taxes so it came down from 2958.25 In FY 23, MRPL maintained a favourable financial metrics with a return on equity (ROE) of 31.10% and return on capital employed (ROCE) of 19.69%. crore rupees to 2655.41 crore rupees.

Planning

SEI

JUNE 25, 2025

trillion in investable assets by 2030, which balloons to $70 trillion in investable assets by 2045.* To capitalize on the financial power of Gen X, advisors must adopt a holistic approach that addresses the diverse needs of their clients. The ultimate differentiator is sophisticated, proactive tax and income optimization.

Education

Trade Brains

APRIL 24, 2023

By 2025, at least 4 million EVs will be sold each year, climbing to 10 million EVs annually by 2030. This falls in line with the company’s target dividend payout ratio of 30-50 percent of the annual standalone PAT (Profit After Tax). At least 25 percent of the auto components produced in India are exported annually. ROCE (%) 24.79

Planning

Trade Brains

SEPTEMBER 15, 2024

The company will also benefit from government tax cuts on cancer drugs, allowing it to make treatments more affordable while increasing market share. Its robust regulatory filings, including 501 for Rest of World (ROW) markets and 74 in the EU, reflect a strong commitment to expansion. Current Market Price ₹ 843.1

Pharmaceutical

Trade Brains

JUNE 5, 2023

Higher income translated into higher profit after tax for the company. However, the nine-month period of FY23 from January to December registered higher sales of Rs 5,749 crore, marginally higher than the full-year FY22 sales. It clocked a net profit of Rs 793 crore in the 9MFY23 period, more than the FY22 net profit of Rs 611 crore.

Planning

Trade Brains

JANUARY 14, 2024

Industry Overview The total output of the global construction market was $10.7 trillion by 2030. The article concludes with a highlight of plans and a summary. trillion in 2020 and is projected to increase to $15.2 This industry is becoming a significant contributor to economic growth, with spending levels expected to reach 13.5%

Planning

Trade Brains

JUNE 10, 2023

By the end of 2030, this industry is expected to reach a market size of 50 billion dollars. Year Total income (Rs in Cr) Profit after tax (Rs in Cr) 2023 3,107.9 An increase in net profit margin indicates that the company also managed its financial obligations and taxes efficiently. 371 2022 2,579.7 178 2021 1,947.5

Pharmaceutical

Trade Brains

JUNE 8, 2023

The global zinc market is projected to grow at a significant rate and reach 1,012.23 thousand tons in volume by 2030. Hindustan Zinc – Financials Revenue and Net Profit Growth The revenues of Hindustan Zinc grew at a CAGR of 10% from Rs 21,118 crore in FY19 to Rs 34,098 crore in FY23.

Planning

WiserAdvisor

FEBRUARY 14, 2024

There are no lock-in periods, penalties, or complex tax considerations. Profits earned from selling sneakers are simply added to your income and taxed accordingly. This greatly simplifies the financial and tax aspects of the investment. billion by 2030. Sneaker investments also come with minimal complications.

Investing

Trade Brains

OCTOBER 16, 2023

from 2020 to 2030. The growth in this sector can be attributed to a number of factors, including the enormous potential of the generics market, advances in the country’s medical infrastructure, the gradual introduction of patented pharmaceuticals, and greater public awareness of health and hygiene, especially in light of COVID-19.

Planning

Trade Brains

OCTOBER 20, 2023

From 2020 to 2030, it is expected to grow at a CAGR of 12.3%. The Indian pharmaceutical sector includes over-the-counter medicines, generic medications, bulk drugs, vaccines, contract research and manufacture, biosimilars, and biologics. This gives the company a CAGR growth of merely 1.48% from FY19 to FY23.

Pharmaceutical